Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111
Debt
Debt-to-Equity Ratio0.17
Current Ratio12.22
Quick Ratio10.25
Price-To-Earnings
Trailing P/E Ratio69.42
Forward P/E Ratio68.46
P/E Growth3.19
Sales & Book Value
Annual Sales$141.24 million
Price / Sales14.82
Cash Flow$0.8675 per share
Price / Cash55.24
Book Value$13.58 per share
Price / Book3.53
Profitability
EPS (Most Recent Fiscal Year)$0.69
Net Income$28.35 million
Net Margins18.48%
Return on Equity6.06%
Return on Assets4.69%
Miscellaneous
Employees476
Outstanding Shares43,690,000
Market Cap$2,087.26
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen Co. (NASDAQ:RGEN) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.15 by $0.02. The biotechnology company had revenue of $44.80 million for the quarter, compared to the consensus estimate of $43.88 million. Repligen had a net margin of 18.48% and a return on equity of 6.06%. The firm's revenue for the quarter was up 46.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.15 earnings per share. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $0.69-0.73 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.70. The company issued revenue guidance of $182-188 million, compared to the consensus revenue estimate of $183.48 million.
What price target have analysts set for RGEN?
7 brokerages have issued twelve-month price targets for Repligen's shares. Their forecasts range from $40.00 to $55.00. On average, they anticipate Repligen's share price to reach $45.00 in the next year. This suggests that the stock has a possible downside of 6.1%. View Analyst Ratings for Repligen.
What is the consensus analysts' recommendation for Repligen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT) and Solid Biosciences (SLDB).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)
- Mr. Jon K. Snodgres, CFO, Sec. & Principal Accounting Officer (Age 52)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director Investor Relations
- Mr. Stephen Tingley, VP of Sales
Has Repligen been receiving favorable news coverage?
News coverage about RGEN stock has trended somewhat positive this week, Accern reports. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Repligen earned a media sentiment score of 0.12 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.18 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Repligen's major shareholders?
Repligen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (0.35%), Boston Advisors LLC (0.30%), Bank of Montreal Can (0.07%) and Amalgamated Bank (0.01%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which institutional investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC and Bank of Montreal Can. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Howard Benjamin, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which institutional investors are buying Repligen stock?
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $47.92.
How big of a company is Repligen?
Repligen has a market capitalization of $2.09 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe.
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (NASDAQ RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
